Less than 20% of patients that could benefit from TAVR are receiving it

 The introduction of transcatheter aortic valve replacement procedures (TAVR) seems to have increased the number of elderly patients hospitalized with severe aortic stenosis, as well as the number of interventions. However, less than one fifth of patients over 85 are intervened, according to a Canadian registry.

 

Given the significant difference in mortality with TAVR, observed even in elderly patients, it is vital to call the attention of clinical cardiologists.

 

Using data of 37,970 patients hospitalized between 2004 and 2013 with primary or secondary aortic stenosis, repeat interventions and mortality rates were followed up at one year.

 

Hospitalization rates increased from 36 to 39% during this period (p<0.001). Similarly, intervention rates (TAVR or surgery) within 12 months after initial hospitalization, increased from 39% in 2004 to 44% in 2013 (p<0.001), with the largest increase in patients over 85 (5% to 18%; p<0.001).

 

A huge limitation to this study, is that there are no registries of echocardiographic data or symptoms, which is why we are not able to tell the number of patients that really needed a valve intervention and would not get it, but we are under the impression that it is lower than it should be.

 

Lastly, after the first hospitalization, mortality at 30 days was 12%, and at one year, 26%. These rates remained stable for the whole study period.

 

For those undergoing a valve intervention (TAVR or surgery), mortality did improve in time.

 

Original Title: Trends in the hospitalization rates and outcomes of patients with aortic stenosis from 2004 to 2013.

Presenter:  Czarnecki A.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...